AbbVie today announced positive topline results from the Phase 3, randomized, placebo-controlled, double-blind AFFIRM study evaluating the efficacy and safety of risankizumab (SKYRIZI®) subcutaneous ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results